I agree with your take, Smilez.
I would also suggest that farming out some production AND having in-house production gives flexibility.
So, for example, Operon et al could be used to churn out the COVID tests in Europe, while the Brisbane line could be directed to produce the Sepsis test strips. Australia is likely to prove a more profitable market for Sepsis tests than Covid.
Anteo takes the cream by making the strips here.
A lot to like about this strategy, IMO.
Ann: EuGeni Test Strip Manufacturing Strategy, page-41
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.79M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 2.0¢ | $3.965K | 195.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1417631 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 95237 | 1 |
View Market Depth
| Last trade - 14.20pm 11/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |